Pharmaceutical

C-Level Diagnostics/Med Device Executive with 25 Years of Experience – CFO and Interim CEO at an oncology focused VC-backed diagnostics company. Secured $50mm in capital and led the transition from a product development company to commercialization and sale of company to a strategic buyer. Previous experience as an advisor, interim management and turnaround executive working with private equity and hedge funds, management teams and board of directors to solve complex business situations, developing and implementing growth strategies and/or turnaround plans focused on achieving bottom-line results. Example assignments include: brought in by $3B investment fund to help accelerate business development activities and identify new business opportunities for a development stage biotechnology company; developed IT strategy and operating plan for a $2B integrated healthcare company and led multiple implementation workstreams. Prior management consulting experience includes advising life sciences companies on over $1B in investment decisions focused on new product development and portfolio strategies, partnering and collaboration, valuation and deal structuring, and significant investments in manufacturing and supply chain infrastructure. Significant international work experience (NA, EU, ME/Asia). Multilingual – Fluent in Danish and Hebrew, working knowledge of Swedish and Norwegian. B.Sc. in Industrial Engineering from one of Scandinavia’s leading technical universities and a top Ivy League MBA. Code PHA358

President/CEO/OTC Pharmaceuticals – Global leader with a proven track record of delivering superior performance across top tier U.S. and international OTC pharmaceutical companies. Full P&L responsibility for companies from $30mm to $350mm. Expertise in leading start-ups and turnarounds as well as negotiating agreements and making/integrating acquisitions. Develops exceptional high performance teams. Experience in the U.S., Europe, Latin America and Canada. Experience in major plant consolidation programs. Most recently President of a PE backed Indian biotech start-up. Prior experience with major British OTC company and U.S. family controlled OTC business. Cross culturally astute; multilingual French and Spanish. Top business school MBA. Code PHA375

Executive at a leading global management consulting firm – focused on marketing and sales, with extensive experience in primary care, consumer, generic and specialty pharmaceuticals, across Europe, US and Japan. Led large-scale transformations in marketing, sales, commercial operations and payor management, delivering 15%+ sales growth, and 20%+ cost reduction. Identified and ensured delivery of $1 billion+ new growth opportunities. Developed innovative product strategy for cardiovascular blockbuster drug. MBA in General Management and BA in Political Science. Code PHA360

Experienced CEO and Group Executive – with a background ranging from a small privately-held company to a large, publicly-traded multinational. P&L experience running five businesses with revenues in excess of $400M. Experience running businesses providing life science research tools, drug discovery platforms, protein engineering technologies, and a host of related services. Operating background includes running service, reagents, and capital equipment businesses sold into the pharmaceutical, biotech, academic, government, agriculture, and industrial biotechnology markets. Results-oriented business leader with proven ability to consistently grow businesses both organically and through acquisition. Deep international experience with global P&L responsibility for > 8 years … lived in Europe on two occasions. Former McKinsey consultant with Ivy League degrees including top-tier MBA. Code PHA348

Entrepreneurial CEO Pharmaceutical and Health Care – COO and General Manager in pharmaceuticals marketing services and healthcare e-learning. Experienced executive/entrepreneur in business development, operations, technology and finance. Has founded and managed three companies from startup – including one NASDAQ technology company. Has significant skill integrating strategic acquisitions into larger company, developing and launching new information services and products. Proven ability to create effective cross-functional teams in complicated situations and deliver results. BS, MS and MBA in Finance (with distinction) from top Ivy University.Code PHA342

CEO in Pharmaceutical Industry – Executive with extensive Pharmaceutical and Biologics experience with both small molecules and biologics at Big Pharma and small entrepreneurial start-up. Significant experience from clinical drug development to approval including regulatory agency negotiation culminating in approval and launch of pharmaceutical products. Ivy League MBA, PhD in Pharmaceutical Chemistry. Code PHA319

President & CEO in Pharmaceutical industry – Currently serves as President and COO of a $100MM fast-growing public company that manufactures OTC products in the contract manufacturing private label and branded markets. Previously served and President and CEO of $150MM privately held manufacturer and marketer of personal care product. B.S. in Business Administration. Code PHA254

COO Pharmaceuticals – Extensive background in drug design and vaccine development. This executive has scale-up and c-GMP production experience, holds 32 patents and has 105 refereed-publications. While responsible for day-to-day operations also led effort for Influenza and Alzheimer’s vaccine development. PhD in Organic Chemistry; BS in Chemistry. Code PHA260

CEO in Pharmaceuticals – A senior executive who is currently responsible for new product marketing and global product management for a leading medical diagnostic and proteomic corporation. Formerly served as an equity, business and technology evaluator as well as a facilitator of restructuring and performance improvement. This executive is a recognized expert in the healthcare field. MBA in Financial Management and Business Policy; BS in Chemistry. Code PHA261

CEO in Pharmaceuticals – Executive with a global management consulting firm with a special expertise in marketing strategy and execution as well as new product launches. Led global R&D organization design process for post merger integration, developed positioning and communication strategy for US launch of global brand. Prior experience with a leading healthcare company includes increasing sales in one division from $20MM to $150MM and reorganizing product portfolio and supply agreements achieving 15% annual sales growth. Ivy League MS degrees in Biomedical Technology and Management, BS in Biochemistry. Code PHA277

President/CEO in the Pharmaceuticals – Experienced executive in both startups and established businesses. Obtained a provisional patent for proprietary database warehousing platforms within the pharmaceutical, chemical and healthcare industries. Designed and marketed database specific programs to provide instant product, clinical and health data to patients, physicians and other healthcare professionals. Previously created a privately held corporation to develop product software and Internet related programs. MA, BA. Code PHA291